Penumbra shares have declined following the release of a report by a short-seller alleging fraudulent activities. This comes amid news that Andrew Left of Citron Research has been charged with market manipulation. Left, known for his role in exposing corporate malfeasance and the $W saga after the CBCV paper, has been a controversial figure in the industry. The government’s fraud case against him has sparked discussions within the biotech community, with commentators like Adam Feuerstein weighing in on the implications. The case highlights the broader issue of market manipulation and its impact on the biotech sector.